ABBOTT Laboratories. (Active Pharmaceutical Ingredient Watch).(boost price for Humira drug)(Brief Article)

Chemical Market Reporter, June, 2003

ABBOTT Laboratories raised its 2003 sales guidance for rheumatoid arthritis drug Humira (adalimumab) by $50 million to $250 million. Guidance for 2004 remains unchanged at over $500 million.

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
Click Here
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement
Click Here